Thierno Diallo, Menonli Adjobimey, Rovina Ruslami, Anete Trajman, Oumou Sow, Joseph Obeng Baah, Guy B Marks, Richard Long, Kevin Elwood, David Zielinski, Martin Gninafon, Diah A Wulandari, Lika Apriani, Chantal Valiquette, Federica Fregonese, Karen Hornby, Pei-Zhi Li, Philip C Hill, Kevin Schwartzman, Andrea Benedetti, Dick Menzies
BACKGROUND: The treatment of latent infection with Mycobacterium tuberculosis is important in children because of their vulnerability to life-threatening forms of tuberculosis disease. The current standard treatment - 9 months of isoniazid - has been associated with poor adherence and toxic effects, which have hampered the effectiveness of the drug. In adults, treatment with 4 months of rifampin has been shown to be safer and to have higher completion rates than 9 months of isoniazid...
August 2, 2018: New England Journal of Medicine